Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples